title: Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis.
abstract: We examined the antithrombotic activity of a novel synthetic inhibitor of factor Xa, YM-60828, in an electrically-induced carotid artery thrombosis model in rats. In the first experiment, the antithrombotic activity of YM-60828 after i.v. infusion was compared with those of heparin, darteparin and argatroban. Test drug was administered by i.v. infusion from 30 min before electrical stimulation to the end of the experiment. YM-60828 at 1 mg/kg/h significantly improved patency status, prolonged the time to occlusive thrombus formation and duration of patency. Heparin at 300 U/kg/h also improved these parameters, but were accompanied by a marked increase in systemic coagulation time. In the second experiment, the antithrombotic activity of YM-60828 after oral administration was compared with those of ticlopidine, cilostazol, aspirin, beraprost, ethyl icosapentate and warfarin. Test drug was orally administered to fasted rats 60 min before electrical stimulation. YM-60828 at 30 mg/kg p.o., but not ticlopidine, cilostazol, aspirin, beraprost, ethyl icosapentate or warfarin, significantly reduced the incidence of occlusion and improved carotid arterial patency. These results suggest that YM-60828 may be a promising antithrombotic agent for the treatment and prevention of arterial thrombosis which can be given by oral as well as intravenous administration.
authors.affiliation: Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, Ibaraki, Japan. kawasat@yamanouchi.co.jp
authors.forename: T
authors.initials: T
authors.lastname: Kawasaki
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: Y
authors.initials: Y
authors.lastname: Sakai
authors.forename: F
authors.initials: F
authors.lastname: Hirayama
authors.forename: H
authors.initials: H
authors.lastname: Koshio
authors.forename: Y
authors.initials: Y
authors.lastname: Taniuchi
authors.forename: Y
authors.initials: Y
authors.lastname: Matsumoto
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage; D000990:Antithrombin III / Q000008:administration & dosage*; D001120:Arginine / Q000031:analogs & derivatives; D002341:Carotid Artery Thrombosis / Q000188:drug therapy*; D004195:Disease Models, Animal; D065427:Factor Xa Inhibitors; D006493:Heparin / Q000008:administration & dosage; D007262:Infusions, Intravenous; D009281:Naphthalenes / Q000008:administration & dosage*; D010875:Pipecolic Acids / Q000008:administration & dosage; D010880:Piperidines / Q000008:administration & dosage*; D051381:Rats; D013449:Sulfonamides
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D009281:Naphthalenes; D010875:Pipecolic Acids; D010880:Piperidines; D013449:Sulfonamides; C111032:YM 60828; D000990:Antithrombin III; D006493:Heparin; D001120:Arginine; C031942:argatroban